New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
11:23 EDTCYTK, BXOptions with increasing implied volatility: CYTK BX
News For CYTK;BX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:33 EDTBXBlackstone, Solops management team announce partnership
Subscribe for More Information
October 20, 2014
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.
October 16, 2014
11:18 EDTBXBlackstone says firm uniquely positioned to benefit from market turmoil
CEO Schwarzman says public markets don't dictate realizations. Comment from Q3 earnings call.
07:10 EDTBXBlackstone reports Q3 ENI 66c, consensus 72c
Subscribe for More Information
05:56 EDTBXStocks with implied volatility movement; BX VALE
Subscribe for More Information
October 15, 2014
15:28 EDTBXNotable companies reporting before tomorrow's open
Subscribe for More Information
06:21 EDTBXBlackstone, Fajr Capital, Mumtalakat acquire minority stake in GEMS
Subscribe for More Information
October 14, 2014
07:25 EDTBXBlackstone October volatility elevated into Q3 and guidance
Subscribe for More Information
October 13, 2014
07:35 EDTCYTKCytokinetics announces development program update for CK-2127107
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use